<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382329</url>
  </required_header>
  <id_info>
    <org_study_id>811001</org_study_id>
    <nct_id>NCT01382329</nct_id>
  </id_info>
  <brief_title>H5N1 Vaccine Study in Japanese Adults</brief_title>
  <official_title>A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Innovations GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain immunogenicity and safety data of two different dose
      levels of an H5N1 pandemic influenza vaccine in a healthy Japanese adult population aged 18
      to 59 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with antibody response to the vaccine strain</measure>
    <time_frame>21 days after 2nd vaccination</time_frame>
    <description>Measurement by single radial hemolysis (SRH) assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects demonstrating seroconversion</measure>
    <time_frame>21 days after 2nd vaccination</time_frame>
    <description>Measurement by SRH assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fold increase of antibody response</measure>
    <time_frame>21 days after 2nd vaccination</time_frame>
    <description>Measurement by SRH assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with antibody response to the vaccine strain</measure>
    <time_frame>21 days after 1st and 21+180 days after 2nd vaccination</time_frame>
    <description>Measurement by SRH (except at 21 days after 2nd vaccination), microneutralization (MN) and hemagglutination inhibition (HI) assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects demonstrating seroconversion</measure>
    <time_frame>21 days after 1st and 21+180 days after 2nd vaccination</time_frame>
    <description>Measurement by SRH (except at 21 days after 2nd vaccination), MN and HI assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response</measure>
    <time_frame>21 days after 1st and 21 + 180 days after 2nd vaccination</time_frame>
    <description>Measurement by SRH, MN and HI assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold increase of antibody response</measure>
    <time_frame>21 days after 1st and 21+180 days after 2nd vaccination as compared to baseline</time_frame>
    <description>Measurement by SRH (except at 21 days after 2nd vaccination), MN and HI assay</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>H5N1 Influenza</condition>
  <arm_group>
    <arm_group_label>Treatment group I / Intramuscular</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>85 subjects to receive 2 intramuscular vaccinations at Dose A on Days 1 and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group II / Intramuscular</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>85 subjects to receive 2 intramuscular vaccinations at Dose B on Days 1 and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group III / Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>85 subjects to receive 2 subcutaneous vaccinations at Dose A on Days 1 and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group IV / Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>85 subjects to receive 2 subcutaneous vaccinations at Dose B on Days 1 and 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)</intervention_name>
    <description>Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm</description>
    <arm_group_label>Treatment group I / Intramuscular</arm_group_label>
    <arm_group_label>Treatment group II / Intramuscular</arm_group_label>
    <arm_group_label>Treatment group III / Subcutaneous</arm_group_label>
    <arm_group_label>Treatment group IV / Subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 18 to 59 years old at the time of screening

          -  Subject is generally healthy, as determined by the investigator´s clinical judgement
             through collection of medical history and performance of a physical examination

          -  Subject is physically and mentally capable of participating in the study and willing
             to adhere to study procedures to include completion of all elements of the study diary

          -  If female of childbearing potential, subject presents with a negative urine pregnancy
             test result within 24 hours prior ot the scheduled first vaccination and agrees to
             employ adequate birth control measures for the duration of the study

        Exclusion Criteria:

          -  Subject has a history of infectin with H5N1 virus or a history of vaccination with an
             H5N1 influenza vaccine

          -  Subject is at high risk of contracting H5N1 influenza infection (e.g. poultry workers)

          -  Subject currently has or has a history of a significant cardiovascular (including
             hypertension), respiratory (including asthma), metabolic, neurological (including
             Guillain-Barré Syndrome and acute disseminated encephalomyelitis), hepatic, rheumatic,
             autoimmune, hematological, gastrointestinal or renal disorder

          -  Subject has any inherited or acquired immunodeficiency

          -  Subject has a disease or is currently undergoing a form of treatment or was undergoing
             a form of treatment within 30 days prior to study entry that can be expected to
             influence immune response. Such treatment includes, but is not limited to: systemic or
             inhaled corticosteroids, radiation treatment, or other immunosuppressive or cytotoxic
             drugs

          -  Subject has a history of severe allergic reactions or anaphylaxis

          -  Subject has a rash, dermatologic condition or tattoos which may interfere with
             injection site reaction rating

          -  Subject has received a blood transfusion or immunoglobulins within 90 days prior to
             study entry

          -  Subject has donated blood or plasma within 30 days prior to study entry

          -  Subject has received any influenza or any live vaccine within 4 weeks or any other
             inactivated vaccine within 2 weeks prior to vaccination in this study

          -  Subject has a functional or surgical asplenia

          -  Subject has a known or suspected problem with alcohol or drug abuse

          -  Subject was administered an investigational drug within 6 weeks prior to study entry
             or is concurrently participating in a clinical study that includes the administration
             of an investigational product

          -  Subject is a member of the team conducting this study or is in a dependent
             relationship with one of the study team members. Dependent relationships include close
             relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of
             the investigator/subinvestigator or site personnel conducting the study

          -  If female, subject is pregnant or lactating at the time of enrollment

          -  Subject has any other condition that disqualifies his/her participation in the study
             in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Geisberger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Innovations GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Co. LTA PS Clinic</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPC Clinic, Medipolis Medical Research Institute</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima-Ken</state>
        <zip>890-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Pharmacology Clinical Research Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka-Fu</state>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis of influenza infection caused by a pandemic influenza virus (H5N1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

